Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

FDA approves first factor XIa inhibitor for secondary stroke prevention

The U.S. Food and Drug Administration has approved Sunharbo (asundexian) 50 mg tablets, in combination with antiplatelet therapy, to reduce the risk for stroke in adults following a recent mild-to-moderate noncardioembolic ischemic stroke or a high-risk transient ischemic attack (TIA).

FDA approves first factor XIa inhibitor for secondary stroke prevention

We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.

Read the original at medicalxpress.com →

More in Health & Medicine

More from Wednesday 18 November →